Expert advisory meeting agreed on special import of Pfizer vaccine
Ready to be vaccinated upon arrival in Korea
[바이오타임즈] The quarantine authorities applied for a special import of US Pfizer vaccines, which will be supplied to Korea after mid-month through the’COVAX Facility’.
The Korea Centers for Disease Control and Prevention (KCDC) announced on the 2nd that at an expert advisory meeting held in conjunction with the Ministry of Food and Drug Safety, consent was reached on the need for special import of Pfizer’s Corona 19 vaccine supplied through the’Covax Facility’.
Experts attending the advisory meeting said that the Pfizer Corona 19 vaccine was approved for use by the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). This decision was made in consideration of participation in quality evaluation as a cooperative review.
In accordance with Article 85-2, Paragraph 1 of the Pharmaceutical Affairs Act, the Ministry of Food and Drug Safety’s special import is a system that makes it possible to manufacture and import preventive and therapeutic drugs without domestic approval in case of a national emergency such as an infectious disease pandemic.
The Agency for Disease Control and Prevention plans to expedite relevant administrative procedures such as supply-related contracts with Pfizer, delivery contracts with UNICEF, and customs clearance permits so that they can be introduced in Korea as soon as the KFDA special approval process is completed.
This time, the Pfizer vaccine coming into Korea through special imports is 117,000 doses (for about 60,000 people).
The Agency for Disease Control and Prevention said, “We will continue to prepare for vaccination so that the vaccine can be vaccinated immediately upon arrival in Korea.”
[바이오타임즈=박세아 기자] [email protected]
Copyright © BioTimes Unauthorized reproduction and redistribution prohibited